[1. World Population Prospects. The 2006 Revision. Highlights. New York, United Nations, 2007.]Search in Google Scholar
[2. Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee Report. Allergy 2004; 59:469-478.10.1111/j.1398-9995.2004.00526.x15080825]Search in Google Scholar
[3. British guideline on the management of asthma: a national clinical guide. British Thoracic Society 2012; 1-151.]Search in Google Scholar
[4. Barnes PJ. PAF, eosinophils and asthma. J Lipid Mediat 1992; 5(2): 155-158.]Search in Google Scholar
[5. Boulet LP, Turcotte H, Brochu A. Persistence of airway obstruction and hyperresponsiveness in subjects with asthma remission. Chest 1994; 105: 1024-1031.10.1378/chest.105.4.10248162720]Search in Google Scholar
[6. Sont JK, Han J, van Krieken JM, Evertse CE, Hooijer R, Willems LN, Sterk PJ.. The relationship between the inflammatory infiltrate in bronchial biopsies and clinical severity of asthma in patients treated with inhaled steroids. Thorax 1996; 51: 496-50210.1136/thx.51.5.4964735948711677]Search in Google Scholar
[7. Fatemi SH, King DP, Reutiman TJ, Folsom TD, Laurence JA, Lee S, Fan YT, Paciga SA, Conti M, Menniti FS. PDE4B polymorphisms and decreased PDE4B expression are associated with schizophrenia. Schizophrenia Res 2008; 101(1-3): 36-49.10.1016/j.schres.2008.01.02918394866]Search in Google Scholar
[8. Lange P, Parner J, Vestbo J, Schnohr P, Jensen G. A 15-year follow-up study of ventilator function adults with asthma. N Engl J Med 1998; 339: 1194-1200.10.1056/NEJM1998102233917039780339]Search in Google Scholar
[9. Grandoch M, Roscioni SS, Schmidt M. The role of Epac proteins, novel cAMP mediators, in the regulation of immune, lung and neuronal function. Br J Pharamacol 2010; 159: 265-284.10.1111/j.1476-5381.2009.00458.x282535019912228]Search in Google Scholar
[10. Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932-946.10.1183/09031936.04.0001430415219010]Search in Google Scholar
[11. Fauci AS, Braunwald E, Kasper DL. Harrison s Principles of Internal Medicine. 17 etd. Mc Graw Hill 2008; 254: 1635-1643.]Search in Google Scholar
[12. Giembycz MA, Field SK. Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD. Drug Des Devel Ther 2010; 4: 147-158.]Search in Google Scholar
[13. Bethke TD, Lahu G.. High absolute bioavailability of the new oral phosphodiesterase-4 inhibitor roflumilast. Int J Clin Pharmacol Ther 2011; 49(1): 51-57.10.5414/CPP4905121176727]Search in Google Scholar
[14. Daxas R. Product information. Nycomed AG, Dubendorf, Switzerland 2012.]Search in Google Scholar
[15. Karish SB, Gagnon JM. The potential role of roflumilast: the new phosphodiesterase-4 inhibitor. Ann Pharmacother 2006; 40: 1096-1104.10.1345/aph.1E65116735669]Search in Google Scholar
[16. Fabbri LM, Beghe B, Yasothan U, Kirkpatrick P. Roflumilast. Nature Reviews Drug Discovery 2010; 9: 761-762.10.1038/nrd327620885403]Search in Google Scholar
[17. Gross NJ, Giembycz MA, Rennard SI. Treatment of chronic obstructive pulmonary disease with roflumilast, a new phosphodiesterase 4 inhibitor. COPD 2010; 7(2): 141-53.10.3109/15412551003758304]Search in Google Scholar
[18. Mokry J, Mokra D, Nosalova G, Beharkova M, Feherova Z. Influence of selective inhibitors of phosphodiesterase 3 and 4 on cough and airway reactivity. J Physiol Pharmacol 2008; 59: 473-82.]Search in Google Scholar
[19. Lipworth BJ. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 2005; 365: 167-175.10.1016/S0140-6736(05)17708-3]Search in Google Scholar
[20. Mokry J, Mokra D. Immunological aspects of phosphodiesterase inhibition in the respiratory system. Respir Physiol Neurobiol 2013; 187(1): 11-17.10.1016/j.resp.2013.02.004]Search in Google Scholar
[21. Mokry J, Joškova M, Mokra D, Christensen I, Nosaľova G. Effects of selective inhibition of PDE4 and PDE7 on airway reactivity and cough in healthy and ovalbumin-sensitized guinea pigs. Adv Exp Med Biol 2013; 756: 57-63.10.1007/978-94-007-4549-0_8]Search in Google Scholar
[22. Mokry J, Nosalova G, Mokra D. Influence of xanthine derivatives on cough and airway reactivity in guinea pigs. J Physiol Pharmacol 2009; 60: 87-91.]Search in Google Scholar
[23. Mokry J, Nosalova G. The influence of the PDE inhibitors on cough reflex in guinea pigs. Bratisl Lek Listy 2011; 112(3): 131-5.]Search in Google Scholar
[24. Mokry J, Mokra D. Phosphodiesterases and their inhibitors in some respiratory system disorders. In: Neonatal Care: New Research. New York: Nova Science Publishers 2013: 29-53.]Search in Google Scholar
[25. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009; 374(9691): 695-703.10.1016/S0140-6736(09)61252-6]Search in Google Scholar
[26. Calverley PM, Rabe KF, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009; 374(9691): 685-94. Erratum in: Lancet 2010; 376(9747): 1146.]Search in Google Scholar
[27. Calzetta L, Page CP, Spina D, et al. Effect of the mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone. J Pharmacol Exp Ther 2013; 346(3): 414-423.10.1124/jpet.113.20464423766543]Search in Google Scholar
[28. Christensen I, Miskovicova H, Porvaznik I, Joskova M, Mokra D, Mokry J. Selective Inhibition of Phosphodiesterase 7 (PDE7) by BRL50481 in Healthy and Ovalbumin-Sensitized Guinea Pigs. Acta Med Mart 2012; 12 (Supple 1): 16-23.10.2478/v10201-011-0023-7]Search in Google Scholar
[29. Medvedova I, Prso M, Eichlerova A, Mokra D, Mikolka P, Mokry J. Influence of roflumilast on airway reactivity and apoptosis in ovalbumin-sensitized Guinea pigs. Adv Exp Med Biol 2015; 838: 11-18.10.1007/5584_2014_7725310957]Search in Google Scholar